Published on : Nov 07, 2016
ALBANY, NY, Nov 07, 2016: The 103-page research study, titled “Global mAb Biosimilars Market 2016–2020,” offers a detailed analysis, focusing on the key growth prospects, latest trends, limitations, product segmentations, and geographical segments of the market. According to the research study, the global mAb biosimilars market is estimated to register a remarkable 57.0% CAGR between 2016 and 2020.
The growing need for cost-effective treatments, favorable government rules and regulations, and the diverse reimbursement benefits for biosimilars are some of the key factors driving the global mAb biosimilars market. In addition, the rise in the number of patent expirations and the increasing number of strategic collaborations and acquisitions are expected to accelerate the growth of the overall market. On the other hand, the risks associated with drug failure, difficulties in patient recruitment for clinical trials, and several manufacturing complexities are projected to curtail the growth of the market in the near future.
On the basis of application, the global mAb biosimilars market has been classified into oncology and chronic and autoimmune diseases. In 2015, the chronic and autoimmune diseases segment led the global market and is expected to remain in the topmost position in the next few years. The easy availability of sophisticated treatment options, a growing geriatric population, and the improved standards concerning healthcare facilities are some of the primary factors estimated to augment the chronic and autoimmune diseases segment in the forecast period.
Click to get more details with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=825438
From a geographical viewpoint, Europe is expected to lead the global mAb biosimilars market and is projected to remain in the lead position throughout the forecast period. The high growth of this region can be attributed to the emergence of innovative and technologically advanced biosimilars. In addition, the flexible and well-defined regulatory framework of the global mAb biosimilars market is estimated to encourage its growth. Germany, Italy, France, Spain, and the U.K. are anticipated to contribute significantly towards the market’s growth.
The mAb biosimilars market worldwide is highly fragmented in nature owing to the presence of a large number of well-established players. Key players in the market are focusing on selling their products to hospitals and commercial laboratories, whose number has increased significantly in the last few years. Additionally, the growing healthcare spending and the rising focus on improving healthcare infrastructure are expected to help key players in enhancing their market penetration in the near future.
The prominent players operating in the mAb biosimilars market across the globe are Hospira, Celltrion, Biocon, and Dr. Reddy’s Laboratories. Some of the other players mentioned in the research study are Pfizer, Baxter, GSK, AstraZeneca, Ranbaxy Laboratories, Hetero Drugs, JCR Pharmaceuticals, LG Lifesciences, Novartis, Boehringer Ingelheim, Aspen, Cipla, Emcure Pharmaceuticals, Sanofi, Pfenex, Daiichi Sankyo, and Roche Holding.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org